Drugs by active ingredient › Neomycin Sulfate + Nystatin + Thiostrepton

Monthly reports by species, five years

Reports by the month FDA received them. Each panel has its own scale; the peak month is printed at the top right. The newest months are incomplete because FDA posts reports with a delay of three to six months.

Reports by year received

2026 covers reports received through March 2026 only.

Signs listed in reports

share of neomycin sulfate + nystatin + thiostrepton reports listing the termall drugs containing thiostreptonall dog reports

1. Deafness54%34
2. Emesis[vomiting]12.7%8
3. Ataxia[unsteady, uncoordinated movement]6.3%4
4. Behavioural disorder NOS[behaviour change, type not specified]6.3%4
5. Impaired hearing6.3%4
6. Lack of efficacy - NOS[the product did not have the expected effect]6.3%4
7. Accidental exposure[exposure that was not intended]4.8%3
8. Anorexia[not eating]4.8%3
9. Ear canal disorder4.8%3
10. Incorrect route of drug administration4.8%3
11. Partial deafness4.8%3
12. Application site hair change[hair change where the product was applied]3.2%2
13. Dyspnoea[difficulty breathing]3.2%2
14. Elevated blood urea nitrogen (BUN)[a kidney value above the normal range]3.2%2
15. Ineffective, other drug(s)[legacy FDA term: the product did not have the expected effect (other drug(s))]3.2%2
16. Lethargy[unusually tired or inactive]3.2%2
17. Otorrhoea3.2%2
18. Tachycardia[fast heart rate]3.2%2
19. Unexplained death3.2%2
20. Vocalisation[crying out or unusual noise]3.2%2
21. Abnormal histology NOS[NOS: not otherwise specified]1.6%1
22. Abnormal menace reflex test1.6%1
23. Adipsia[not drinking]1.6%1
24. Allergic oedema1.6%1
25. Anaphylactoid reaction[sudden allergic-type reaction]1.6%1
26. Anxiety1.6%1
27. Application site erythema[reddened skin where the product was applied]1.6%1
28. Application site hair loss[hair loss where the product was applied]1.6%1
29. Application site oedema[oedema where the product was applied]1.6%1
30. Azotaemia[raised kidney values in blood]1.6%1

Top 30 of 96 coded terms (VeDDRA, the veterinary reporting dictionary; plain-language gloss in brackets). One report can list several terms. The ticks show how often the same term appears in a wider pool of reports; they describe the reports, and FDA cautions that such figures cannot be used to estimate risk or to compare one product with another. openFDA masks brand and manufacturer names in adverse event records, so the reports counted here cannot be attributed to a particular brand.

Outcomes and report types

Coloured bar: reports naming neomycin sulfate + nystatin + thiostrepton. Grey bar: all 1,357,245 reports in the database. Outcomes are the status at the time of the last report, as stated by the reporter; a report covering several animals can carry more than one outcome. FDA has not necessarily determined whether any drug played a part in any outcome.

Species and breeds in the reports

Breed shares follow how common each breed is. Crossbred animals and reports with no breed stay in the species figure only.

Age, weight and route

Route of administration stated in reports: auricular (otic) (10), topical (6), ophthalmic (1).

In context

The thiostrepton pool is every report naming thiostrepton alone or in any combination; this combination accounts for 5.3% of it. Shares are of reports, not of animals treated. The number of doses sold is not public, so none of these figures is a rate of occurrence, and differences between columns reflect which animals receive a drug and who reports as much as anything else.

Other ingredient sets sharing an ingredient

Listed for navigation, ordered by report count. FDA states that these data "cannot be used to estimate the risk associated with the product or compare one drug or device product with another": drugs differ in formulation, in the animals they are given to, in sales volume and in years on the market. A report's ingredient field can be incomplete, so reports about one product may sit under more than one set.

Where this comes from. Counts are built from the openFDA Animal & Veterinary adverse event bulk files released 28 Sep 2026, which hold reports FDA's Center for Veterinary Medicine received through 31 Mar 2026. openFDA masks brand and manufacturer names in these files, so drugs are counted by the active ingredients each record discloses and no figure is attributed to a brand, application or company. Ingredient names, and the separate reference lists of approved products, follow the FDA Green Book as of 1 Oct 2026. Drug entries are grouped by the active ingredients their unmasked ingredient field discloses; the application number that records also carry is not used. No report text, lot numbers or reporter details are published. See the methodology and sources; FDA's record is authoritative, and corrections are handled within five working days.